Rep. Gilbert Ray Cisneros, Jr. Buys Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on January 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
• Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Agios Pharmaceuticals NASDAQ: AGIO on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Lantheus NASDAQ: LNTH on 1/28/2025.

Crinetics Pharmaceuticals Price Performance

Shares of NASDAQ CRNX traded down $0.05 during trading hours on Friday, hitting $35.21. 643,625 shares of the stock were exchanged, compared to its average volume of 1,144,310. The company's 50 day moving average is $45.20 and its 200 day moving average is $51.11. The firm has a market capitalization of $3.27 billion, a P/E ratio of -9.44 and a beta of 0.56. Crinetics Pharmaceuticals, Inc. has a one year low of $34.07 and a one year high of $62.53.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CRNX. Venturi Wealth Management LLC bought a new stake in Crinetics Pharmaceuticals during the fourth quarter worth about $41,000. Headlands Technologies LLC acquired a new stake in Crinetics Pharmaceuticals during the 4th quarter valued at approximately $52,000. Harvest Fund Management Co. Ltd bought a new position in Crinetics Pharmaceuticals during the 4th quarter valued at $66,000. Values First Advisors Inc. bought a new position in Crinetics Pharmaceuticals during the 3rd quarter valued at $84,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $91,000. 98.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CRNX shares. HC Wainwright restated a "buy" rating and issued a $81.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. Citigroup increased their target price on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a research report on Thursday, November 14th. TD Cowen assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating for the company. Wolfe Research assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 4th. They set a "peer perform" rating for the company. Finally, JMP Securities reiterated a "market outperform" rating and set a $87.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday, December 16th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, Crinetics Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $72.64.

Insider Transactions at Crinetics Pharmaceuticals

In other news, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $39.07, for a total transaction of $195,350.00. Following the sale, the insider now directly owns 31,748 shares in the company, valued at $1,240,394.36. The trade was a 13.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jeff E. Knight sold 501 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.52, for a total value of $28,316.52. Following the completion of the sale, the chief operating officer now directly owns 51,653 shares of the company's stock, valued at approximately $2,919,427.56. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.00% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.